An interventional study of Probiotic 2 × 10^8 and Placebo capsule in Atopic Dermatitis and Eczema, sponsored by National Cheng-Kung University Hospital. Enrolling by invitation at 1 site in Taiwan. Open to participants aged 3 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by National Cheng-Kung University Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies in Dermatitis, Atopic with a site in Taiwan — 10 open to participants now, 21 under way, 8 of them phase 3. Dermatitis, Atopic · Taiwan.
Among the 70 studies in Dermatitis, Atopic with a site in Taiwan, this one is the 43rd largest by planned enrollment of the 60 interventional ones that give a count, is one of 5 that started in 2026, is one of 9 with no phase, reaches primary completion later than 12 of the 20 other live ones, and was the 70th registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →10 of the 70 studies in Dermatitis, Atopic with a site in Taiwan are open now. Recruiting first, the newest first:
Arjil Pharmaceuticals LLC · Sites in Taiwan
Ages 18+
Pfizer · Sites in Taiwan, United States, Canada and 1 more country
Ages 12+
Novartis Pharmaceuticals · Sites in Taiwan, United States, Argentina and 14 more countries
Ages 18–100
Taipei Medical University Shuang Ho Hospital · Sites in Taiwan
Ages 6–17
En Chu Kong Hospital · Sites in Taiwan
Ages 18–65
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 195 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 96 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.
This study: 3 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 22 · Phase 3 30 · Phase 4 1
First in 2005; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 90 is close to the median of 82 across 1,246 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 290 across the 60 interventional studies, 130 across the 9 observational. Of the 44 that completed or were terminated, 23 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
51 of 70 have an industry lead sponsor. The 10 most frequent:
National Cheng-Kung University Hospital is the lead sponsor of 279 studies on the registry; 70 are open to participants now.
National Cheng-Kung University Hospital has 2 studies filed under Dermatitis, Atopic — fewer than ten, so there is no comparison to draw.
5 of the studies in Dermatitis, Atopic with a site in Taiwan that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06850311Phase 3En Chu Kong HospitalHerbal Ointment in Treating Atopic Dermatitis Topically | 2027-03-01 |
| NCT06241118Phase 3SanofiA Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor | 2027-09-30 |
| NCT07230860Janssen Research & Development, LLCA Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis | 2026-11-19 |
| NCT03992417SanofiObservational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD) | 2027-03-31 |
| NCT06397911Oneness Biotech Co., Ltd.Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis | 2027-05-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 70 studies in Dermatitis, Atopic with a site in Taiwan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn whether probiotics isolated from breast milk and healthy infant feces can reduce the severity of atopic dermatitis (eczema) in children aged 3 to 18 years with moderate-to-severe disease. The main questions it aims to answer are:
Participants will:
Detailed Description Background: Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disorder that typically manifests in infancy and may persist into adulthood, with an estimated prevalence of approximately 21% among Taiwanese children aged 6 months to 18 years. Its pathogenesis is multifactorial, involving genetic susceptibility, epidermal barrier dysfunction, and immune dysregulation. Type 2 cytokines, including IL-4, IL-5, IL-13, and IL-31, suppress keratinocyte barrier proteins and lipids, promote IgE production, and activate eosinophils and mast cells. IL-4 and IL-13 also act directly on itch-sensory neurons and potentiate IL-31 signaling. IL-31, often termed the "itch cytokine", further induces Th1-associated mediators (IFN-γ, TNF-α, and IL-17) via the JAK/STAT pathway, thereby contributing to disease chronicity.
Rationale: Accumulating evidence implicates intestinal dysbiosis in AD pathogenesis through the gut-skin axis, with depletion of commensal Lactobacillus and Bifidobacterium consistently associated with disease onset and exacerbation. In a prospective healthy full-term birth cohort (n = 338), the investigators observed that infants who developed AD by 12 months of age exhibited significantly lower fecal abundance of Bifidobacterium, particularly Bifidobacterium longum, at 16 weeks of age. A total of 257 Lactobacillus and Bifidobacterium isolates were subsequently obtained from human breast milk and healthy infant feces and screened in vitro for acid and bile tolerance, immunomodulatory activity, and attenuation of LPS-induced cytokine production in peripheral blood mononuclear cells. Two lead candidates, B. longum and B. bifidum [TBC: final product strains], ameliorated skin lesions, improved skin hydration, and reduced transepidermal water loss in a diet-induced HR-1 hairless mouse model of AD. However, the clinical efficacy and immunological mechanisms of these strains in children remain to be established.
Study design and intervention: This is a single-center, prospective, randomized, double-blind, placebo-controlled, parallel-group trial conducted at National Cheng Kung University Hospital, Tainan, Taiwan. Ninety children aged 3 to 18 years with moderate-to-severe AD receiving standard care are randomized in a 2:1 ratio to probiotic (n = 60) or placebo (n = 30). The investigational product is manufactured in a GMP- and FSSC 22000-certified facility (New Bellus Enterprises Co., Ltd.). Each capsule contains 2 × 10\^9 CFU [TBC: per gram or per capsule]; the placebo capsule contains excipient only and is identical in appearance. Participants take one capsule orally twice daily for 12 weeks as an adjunct to standard therapy, which continues at the discretion of the attending physician. For young children or those unable to swallow capsules, the contents may be dispersed in milk or juice at no more than 40 °C.
Assessments: Disease severity is assessed with the Patient-Oriented SCORAD (PO-SCORAD), and health-related quality of life with [TBC: instrument], at randomization and at weeks 2, 4, 8, and 12. Fecal samples are collected at baseline and at weeks 4 and 12, stored frozen, and analyzed by 16S rRNA gene (V3-V4) amplicon sequencing to characterize gut microbial diversity and taxonomic composition. Peripheral blood (10 mL) is obtained at baseline and week 12 for T-cell subset profiling by flow cytometry and for quantification of serum total IgE, histamine, and IL-31 by ELISA. Participants who experience clinical deterioration are withdrawn from the study and managed with alternative therapy.
Objectives: The study aims to determine the clinical efficacy of the candidate probiotics in reducing AD severity and pruritus, and to elucidate whether clinical response is associated with restoration of gut microbial homeostasis and modulation of the type 2/IL-31 inflammatory axis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One probiotic(2\*10\^8) twice daily for 12 weeks, in addition to regular atopic dermatitis treatment.
Dietary Supplement: Probiotic 2 × 10^8
One probiotic(2\*10\^10) twice daily for 12 weeks, in addition to regular atopic dermatitis treatment.
Dietary Supplement: Probiotic 2 × 10^10
One identical-appearing placebo capsule twice daily for 12 weeks, in addition to regular atopic dermatitis treatment.
Other: Placebo capsule
Capsule containing 2 × 10\^8 CFU \[TBC: per gram or per capsule\] of Bifidobacterium longum and Bifidobacterium bifidum \[TBC: final strains\] isolated from breast milk and healthy infant feces. Taken orally twice daily for 12 weeks; contents may be mixed with milk or juice at no more than 40 °C.
Capsule of identical appearance containing excipient only, without probiotic bacteria. Taken orally twice daily for 12 weeks.
Capsule containing 2 × 10\^10 CFU \[TBC: per gram or per capsule\] of Bifidobacterium longum and Bifidobacterium bifidum \[TBC: final strains\] isolated from breast milk and healthy infant feces. Taken orally twice daily for 12 weeks; contents may be mixed with milk or juice at no more than 40 °C.
Change in Eczema Area and Severity Index (EASI) score from baseline to week 12
Clinician-assessed EASI. Score range 0-72; higher scores indicate more severe disease.
Time frame: Baseline, week4, week8, week 12
Change in gut microbial
Relative abundance (%) of the gut microbial from 16S rRNA gene (V1-V9) sequencing of stool.
Time frame: Baseline, weeks 4 and 12
Change in PO-SCORAD
Patient-Oriented SCORAD completed by the participant or primary caregiver (range 0-103; higher = worse).
Time frame: Baseline, week4, week8, week 12
Change in quality of life
For different ages, IDQOL, CDLQI, or DLQI, completed by the participant or primary caregiver.(range:0-30)
Time frame: Baseline, week4, week8, week 12
Change in serum total IgE
Serum total IgE concentration (IU/mL).
Time frame: Baseline and week 12
Change in serum histamine
Serum histamine concentration measured by ELISA (ng/mL).
Time frame: Baseline and week 12
Change in serum IL-4
Serum interleukin-4 concentration measured by ELISA (pg/mL).
Time frame: Baseline and week 12
Change in serum IL-13
Serum interleukin-13 concentration measured by ELISA (pg/mL).
Time frame: Baseline and week 12
Change in serum IL-31
Serum interleukin-31 concentration measured by ELISA (pg/mL).
Time frame: Baseline and week 12
Change in white blood cell count
Total white blood cell count from complete blood count (cells/μL).
Time frame: Baseline and week 12
Change in absolute lymphocyte count
Absolute lymphocyte count (cells/μL).
Time frame: Baseline and week 12
Change in absolute CD3+ T-cell count
Absolute CD3+ T-cell count measured by flow cytometry (cells/μL).
Time frame: Baseline and week 12
Change in absolute CD4+ helper T-cell count
Absolute CD4+ T-cell count measured by flow cytometry (cells/μL).
Time frame: Baseline and week 12
Change in absolute CD8+ suppressor/cytotoxic T-cell count
Absolute CD8+ T-cell count measured by flow cytometry (cells/μL).
Time frame: Baseline and week 12
Change in CD4+/CD8+ T-cell ratio
Ratio of CD4+ to CD8+ T cells measured by flow cytometry (ratio, unitless).
Time frame: Baseline and week 12
Plan to share: No — The informed consent does not cover the sharing of individual participant data outside the study team. De-identified data are stored at National Cheng Kung University Hospital until 2050, and aggregate results will be published in medical conferences and journals.
No publications or documents are linked to this record.
Started Jun 2026 (actual). Primary completion is estimated for Dec 2027, 18 months after the start.
Of 113 non-industry interventional studies with no phase under Dermatitis, Atopic, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's planned 18 months is close to that.
Counting every sponsor, half of 182 studies reached it within 15 months; a quarter within 6 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Cheng-Kung University Hospital →